Expression of High Mobility Group Box - B1 (HMGB-1) and Matrix Metalloproteinase-9 (MMP-9) in Non-small Cell Lung Cancer (NSCLC)

  • Wang, Jing-Luan (Department of Critical Care Medicine, Qilu Hospital, Shandong University) ;
  • Wu, Da-Wei (Department of Critical Care Medicine, Qilu Hospital, Shandong University) ;
  • Cheng, Zhao-Zhong (Department of Respiratory Medicine, The Affiliated Hospital of Qingdao University) ;
  • Han, Wei-Zhong (Department of Respiratory Medicine, The Affiliated Hospital of Qingdao University) ;
  • Xu, Sheng-Wei (Department of Respiratory Medicine, The Third People's Hospital of Qingdao) ;
  • Sun, Ni-Na (Department of Respiratory Medicine, The Affiliated Hospital of Qingdao University)
  • Published : 2014.06.30


Objective: This study evaluated the expression level of high mobility group box-B1 (HMGB-1) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC) inmorder to reveal any relation with development and prognosis. Methods: NSCLC and normal tissues were selected from 30 patients at age of 30-73, and used for RT-PCR and Western blot analyses of HMGB-1. A total of 100 paraffin embedded NSCLC tissues were also isolated from patients through surgical resection, and used for detection of HMGB-1 by immunohistochemistry. In addition, 50 samples were also applied for MMP-9 detection, and 30 normal tissues were considered as controls. Correlation analysis of HMGB-1 and MMP-9 was carried out by Pearsons correlation coefficient. Results: The average expression level of HMGB-1 in NSCLC patients was significantly higher than in normal lung tissues. In addition, patients in III-IV period exhibit significantly higher positive rate of HMGB-1 when compared with I-II period cases. Furthermore, a positive correlation with HMGB-1 was found in the expression of MPP-9. Conclusion: HMGB-1 was highly expressed in NSCLC, which may become a prognostic and predictive marker for NSCLC. Besides, MPP-9 was positively correlated with HMGB-1.


  1. Zheng Z, Chen T, Li X, et al (2007). DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. New Engl J Med, 356, 800-8.
  2. Wu F, Zhao ZH, Ding ST, et al (2013). High mobility group box 1 protein is methylated and transported to cytoplasm in clear cell renal cell carcinoma. Asian Pac J Cancer Prev, 14, 5789-95.
  3. Yang H, Wang H, Czura CJ , Tracey K J (2005). The cytokine activity of HMGB1. J Leukocyte Biol, 78, 1-8.
  4. Zhang QW, Liu L, Chen R, et al (2012). Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 13, 2903-8.
  5. Stetler-Stevenson W, Liotta L , Kleiner D (1993). Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J, 7, 1434-41.
  6. Simon G R, Sharma S, Cantor A, et al (2005). ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. CHEST Journal, 127, 978-83.
  7. Sims GP, Rowe DC, Rietdijk ST, et al (2009). HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol, 28, 367-88.
  8. Song J, Su H, Zhou YY , Guo LL (2013). Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: a meta-analysis. Asian Pac J Cancer Prev, 14, 1615-21.
  9. Taguchi A, Blood DC, del Toro G, et al (2000). Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature, 405, 354-60.
  10. Takada M, Hirata K, Ajiki T, et al (2004). Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology, 51, 928-30.
  11. Tsao MS, Aviel-Ronen S, Ding K, et al (2007). Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer. J Clin Oncol, 25, 5240-7.
  12. Volp K, Brezniceanu ML, Bosser S, et al (2006). Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut, 55, 234-42.
  13. Wang H, Yang H, Tracey K (2004). Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med, 255, 320-31.
  14. Wang L, Wang Q, Li HL , Han LY (2013). Expression of MiR200a, miR93, metastasis-related gene RECK and MMP2/MMP9 in human cervical carcinoma--relationship with prognosis. Asian Pac J Cancer Prev, 14, 2113-8.
  15. Park SI, Lee HR, Kim S, et al (2012). Time-sequential modulation in expression of growth factors from plateletrich plasma (PRP) on the chondrocyte cultures. Mol Cell Biochem, 361, 9-17.
  16. Miller VA, Riely G J, Zakowski M F, et al (2008). Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol, 26, 1472-8.
  17. Nomoto K, Tsuta K, Takano T, et al (2006). Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol, 126, 608-15.
  18. Olaussen KA, Dunant A, Fouret P, et al (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. New Engl J Med, 355, 983-91.
  19. Quint LE, Tummala S, Brisson LJ, et al (1996). Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg, 62, 246-50.
  20. Rodenhuis S, van de Wetering M L, Mooi W J, et al (1987). Mutational activation of the K-ras oncogene. New Engl J Med, 317, 929-35.
  21. Salgia R (2011). Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer, 117, 3889-99.
  22. Sasahira T, Kirita T, Oue N, et al (2008). High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci, 99, 1806-12.
  23. Shang GH, Jia CQ, Tian H, et al (2009). Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Resp Med, 103, 1949-53.
  24. Kuniyasu H, Oue N, Wakikawa A, et al (2002). Expression of receptors for advanced glycation end, products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol, 196, 163-70.
  25. Gao XH, Yang XQ, Wang BC, et al (2013). Overexpression of twist and matrix metalloproteinase-9 with metastasis and prognosis in gastric cancer. Asian Pac J Cancer Prev, 14, 5055-60.
  26. Goldstraw P, Ball D, Jett JR, et al (2011). Non-small-cell lung cancer. The Lancet, 378, 1727-40.
  27. Klein T , Bischoff R (2011). Physiology and pathophysiology of matrix metalloproteases. Amino acids, 41, 271-90.
  28. Kuniyasu H, Yano S, Sasaki T, et al (2005). Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol, 166, 751-9.
  29. Li LN, Zhou X, Gu Y, Yan J (2013). Prognostic value of MMP-9 in ovarian cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 4107-13.
  30. Lin ZM, Zhao JX, Duan XN, et al (2014). Effects of tissue factor, PAR-2 and MMP-9 expression on human breast cancer cell line MCF-7 invasion. Asian Pac J Cancer Prev, 15, 643-6.
  31. Liu PL, Tsai JR, Hwang JJ, et al (2010).High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Resp Cell Mol, 43, 530-8.
  32. Maeda S, Hikiba Y, Shibata W, et al (2007). Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Bioph Res Co, 360, 394-400.
  33. Mao XJ, Wang GF, Chen ZJ, et al (2012). Expression of HMGB1 and its clinical significance in T-cell lymphoma. Asian Pac J Cancer Prev, 13, 5569-71.
  34. Eberhard DA, Johnson BE, Amler LC, et al (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 23, 5900-9.
  35. Bepler G, Sharma S, Cantor A, et al (2004). RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol, 22, 1878-85.
  36. Brezniceanu ML, Volp K, Bosser S, et al (2003). HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J, 17, 1295-7.
  37. Dumitriu IE, Baruah P, Manfredi AA, et al (2005). HMGB1: guiding immunity from within. Trends Immunol, 26, 381-7.
  38. Ellerman JE, Brown CK, de Vera M, et al (2007). Masquerader: high mobility group box-1 and cancer. Clin Canc Res, 13, 2836-48.
  39. Ettinger D, Akerley W, Bepler G, et al (2008). Non-small cell lung cancer. J Natl Compr Canc Netw, 6, 228.
  40. Ettinger DS, Akerley W, Bepler G, et al (2010). Non-small cell lung cancer. JNCCN, 8, 740-801.

Cited by

  1. Expression of RECK and MMPs in Hepatoblastoma and Neuroblastoma and Comparative Analysis on the Tumor Metastasis vol.16, pp.9, 2015,
  2. High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer vol.36, pp.12, 2015,
  3. Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in lung adenocarcinoma vol.36, pp.5, 2015,
  4. Expression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinoma vol.14, pp.1, 2017,